Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Ann Surg Oncol ; 27(3): 752-762, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31732946

RESUMEN

BACKGROUND: The aim of this work is to evaluate pattern of care and clinical outcome in a large series of patients with in-breast recurrence (IBR), after quadrantectomy and intraoperative radiation therapy with electrons (IOERT) as partial breast irradiation. PATIENTS AND METHODS: Patients with IBR after IOERT, treated with salvage surgery ± adjuvant reirradiation (re-RT), were selected from a multiinstitution database. Disease-free survival (DFS), overall survival (OS), cumulative incidence of second IBR, and distant metastases (DM) were estimated. RESULTS: A total of 224/267 patients from seven institutions were included. Primary tumors received 21 Gy. Median time to first IBR was 4.3 years (range 2.6-6.1 years). Salvage mastectomy and repeat quadrantectomy were performed in 135 (60.3%) and 89 (39.7%) patients, followed by adjuvant re-RT in 21/135 (15.5%) and 63/89 (70.8%), respectively. Median follow-up after salvage treatment was 4.1 years. Overall, 5- and 8-year outcomes were as follows: cumulative incidence of second IBR: 8.4% and 14.8%; cumulative incidence of DM: 17.1% and 22.5%; DFS: 67.4% and 52.5%; OS: 89.3% and 74.7%. The risk of second IBR was similar in the salvage mastectomy and repeat quadrantectomy + RT groups [hazard ratio (HR) 1.41, p = 0.566], while salvage mastectomy patients had greater risk of DM (HR 3.15, p = 0.019), as well as poorer DFS (HR 2.13, p = 0.016) and a trend towards worse OS (HR 3.27, p = 0.059). Patients who underwent repeat quadrantectomy alone had worse outcomes (second IBR, HR 5.63, p = 0.006; DFS, HR 3.21, p = 0.003; OS, HR 4.38, p = 0.044) than those adding re-RT. CONCLUSIONS: Repeat quadrantectomy + RT represents an effective salvage approach and achieved local control comparable to that of salvage mastectomy.


Asunto(s)
Neoplasias de la Mama/mortalidad , Electrones/efectos adversos , Mastectomía/mortalidad , Recurrencia Local de Neoplasia/mortalidad , Traumatismos por Radiación/mortalidad , Radioterapia Adyuvante/mortalidad , Anciano , Neoplasias de la Mama/patología , Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Carcinoma Ductal de Mama/mortalidad , Carcinoma Ductal de Mama/patología , Carcinoma Ductal de Mama/radioterapia , Carcinoma Ductal de Mama/cirugía , Carcinoma Lobular/mortalidad , Carcinoma Lobular/patología , Carcinoma Lobular/radioterapia , Carcinoma Lobular/cirugía , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Periodo Intraoperatorio , Persona de Mediana Edad , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/radioterapia , Recurrencia Local de Neoplasia/cirugía , Pronóstico , Estudios Prospectivos , Traumatismos por Radiación/etiología , Traumatismos por Radiación/patología , Dosificación Radioterapéutica , Estudios Retrospectivos , Tasa de Supervivencia
2.
Future Oncol ; 10(14): 2111-20, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25471025

RESUMEN

AIMS: To evaluate technical issues and clinical outcomes after postoperative volumetric-modulated arc therapy (VMAT) in two cases of malignant lacrimal gland cancer. PATIENTS & METHODS: Patients were treated by postoperative VMAT and post-treatment clinical outcomes were followed-up to 18 months. RESULTS: Dosimetric results were acceptable and acute toxicity was manageable in both patients. No evidence of disease was found at latest follow-up. One patient underwent corneal transplant for central corneal ulceration, experiencing reduction of visual acuity. CONCLUSION: Postoperative VMAT for treatment of lacrimal gland tumors offers improved outcome, with manageable side effects. In the context of photon beam radiotherapy, VMAT emerged as a valuable treatment option for these malignant tumors.


Asunto(s)
Carcinoma/radioterapia , Neoplasias del Ojo/radioterapia , Aparato Lagrimal/patología , Cuidados Posoperatorios , Radioterapia de Intensidad Modulada , Adulto , Carcinoma/diagnóstico , Carcinoma/cirugía , Neoplasias del Ojo/diagnóstico , Neoplasias del Ojo/cirugía , Femenino , Humanos , Aparato Lagrimal/cirugía , Imagen por Resonancia Magnética , Masculino , Dosificación Radioterapéutica , Radioterapia de Intensidad Modulada/métodos , Resultado del Tratamiento
3.
Cancers (Basel) ; 14(21)2022 Oct 22.
Artículo en Inglés | MEDLINE | ID: mdl-36358608

RESUMEN

We investigated how hypofractionated radiotherapy (HFRT) and stereotactic body radiotherapy (SBRT) may impact immune cells in different type of tumors. A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The PubMed, Embase and Cochrane databases were searched. Overall, 11 studies met the inclusion criteria and were eligible for the present analysis. Both HFRT and SBRT have different impact on lymphocyte subpopulations, confirming their immunomodulatory effect which may have a crucial role in future combined treatment with new emergent therapies such as immunotherapy. Further studies are needed to shed more light on this emerging topic to ultimately improve patient care, treatment and clinical benefits for cancer patients.

4.
Front Oncol ; 12: 953810, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36313648

RESUMEN

In selected low-risk breast cancer patients, accelerated partial breast irradiation (APBI) may represent an alternative option to the whole breast irradiation to reduce the volume of irradiated breast and total treatment duration. In the last few years, preliminary data from clinical trials showed that stereotactic partial breast radiotherapy may have the advantage to be less invasive compared to other APBI techniques, with preliminary good results in terms of local toxicity and cosmesis: the use of magnetic resonance, fiducial markers in the tumor bed, and new breast devices support both a precise definition of the target and radiation planning. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021257856, identifier CRD42021257856.

5.
Rheumatology (Oxford) ; 49(6): 1153-7, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20236956

RESUMEN

OBJECTIVES: To evaluate, by musculoskeletal ultrasound (MSUS), articular involvement in primary SS (pSS) patients by analysing hand and wrist changes, and to correlate them with clinical evaluation and laboratory tests. METHODS: Thirty-two pSS patients underwent clinical and laboratory examinations, including the SS Disease Damage Index (SSDDI) and the SS Disease Activity Index (SSDAI). MSUS was performed in all patients in both hands and wrists, evaluating the presence of inflammation within joints and periarticular tissues, and the existence of permanent joint damage. For synovial hypertrophy, joint effusion and Doppler signal findings, a semi-quantitative score (0-3) was used indicating the degree of involvement (0 = normal; 1 = mild change; 2 = moderate change; and 3 = severe change). For tenosynovitis and bone erosions, a dichotomous score (0 = absent and 1 = present) was applied. RESULTS: Sonographic signs of synovitis of the radio-ulno-carpal joint were found in 17 (26.5%) out of 64 wrists. Wrist synovitis was found in 12 (37.5%) out of 32 patients. Ultrasonographic examination of the hand did not show significant changes. A statistically significant correlation was found between SSDDI score and the degree of sonographic signs of synovial proliferation in the wrist (P = 0.04). The correlation between the incidence of clinical involvement and the presence of pathological ultrasonographic findings was not significant. Patients with synovitis had a higher median age and higher median SSDDI (P = 0.004). CONCLUSIONS: In pSS patients, MSUS may be considered a useful tool for detecting synovitis since articular involvement can often be silent but correlated with SSDDI.


Asunto(s)
Síndrome de Sjögren/diagnóstico por imagen , Sinovitis/diagnóstico por imagen , Adulto , Anciano , Femenino , Mano/diagnóstico por imagen , Humanos , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Síndrome de Sjögren/fisiopatología , Estadística como Asunto , Membrana Sinovial/diagnóstico por imagen , Sinovitis/fisiopatología , Ultrasonografía/métodos , Muñeca/diagnóstico por imagen , Articulación de la Muñeca/diagnóstico por imagen
6.
Breast ; 49: 194-200, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31931265

RESUMEN

Artificial intelligence demonstrated its value for automated contouring of organs at risk and target volumes as well as for auto-planning of radiation dose distributions in terms of saving time, increasing consistency, and improving dose-volumes parameters. Future developments include incorporating dose/outcome data to optimise dose distributions with optimal coverage of the high-risk areas, while at the same time limiting doses to low-risk areas. An infinite gradient of volumes and doses to deliver spatially-adjusted radiation can be generated, allowing to avoid unnecessary radiation to organs at risk. Therefore, data about patient-, tumour-, and treatment-related factors have to be combined with dose distributions and outcome-containing databases.


Asunto(s)
Inteligencia Artificial , Neoplasias de la Mama/radioterapia , Medicina de Precisión/métodos , Planificación de la Radioterapia Asistida por Computador/métodos , Femenino , Humanos , Órganos en Riesgo , Dosificación Radioterapéutica
8.
Asian Pac J Cancer Prev ; 15(18): 7559-62, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25292028

RESUMEN

Currently the most important prognostic factor in lung cancer is the stage. In the current lung TNM classification system, N category is defined exclusively by anatomic nodal location though, in other type of tumours, number of lymph nodes is confirmed to be a fundamental prognostic factor. Therefore we evaluated the number of mediastinal lymph nodes as a prognostic factor in locally advanced NSCLC after multimodality treatment, observing a significant effect of the number of lymph nodes in terms of OS (p<0.01) and DFS (p<0.001): patients with a low number of positive mediastinal nodes have a better prognosis.


Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/secundario , Neoplasias Pulmonares/patología , Neoplasias del Mediastino/secundario , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/terapia , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/terapia , Metástasis Linfática , Masculino , Neoplasias del Mediastino/mortalidad , Neoplasias del Mediastino/terapia , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Estudios Retrospectivos , Literatura de Revisión como Asunto , Tasa de Supervivencia
10.
Tumori ; 99(5): e237-40, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24362877

RESUMEN

Extracranial metastases from glioblastoma multiforme (GBM) are a very rare event, even if an increasing incidence has been documented. We report the case of a young woman with primary GBM who developed bone metastases without local brain relapse. Because of persistent headache and visual disturbances, in March 2011 the patient underwent magnetic resonance imaging (MRI) evidencing a temporoparietal mass, which was surgically resected. Histology revealed GBM. She was given concomitant chemoradiotherapy according to the Stupp regimen. After a 4-week break, the patient received 6 cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days. In December 2011 she complained of progressive low back pain, and MRI showed multiple bone metastases from primary GBM, confirmed by histology. Cases of metastatic GBM in concurrence with a primary brain tumor or local relapse are more common in the literature; only a few cases have been reported where extracranial metastases from GBM occurred without any relapse in the brain. Here we report our experience.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/análisis , Conservadores de la Densidad Ósea/uso terapéutico , Neoplasias Óseas/secundario , Neoplasias Encefálicas/patología , Difosfonatos/uso terapéutico , Glioblastoma/secundario , Imidazoles/uso terapéutico , Adulto , Biopsia con Aguja Fina , Neoplasias Óseas/terapia , Dacarbazina/administración & dosificación , Dacarbazina/análogos & derivados , Progresión de la Enfermedad , Epirrubicina/administración & dosificación , Epirrubicina/efectos adversos , Femenino , Proteína Ácida Fibrilar de la Glía/análisis , Glioblastoma/terapia , Humanos , Inmunohistoquímica , Metástasis Linfática , Mucina-1/análisis , Compuestos de Nitrosourea/administración & dosificación , Compuestos de Nitrosourea/efectos adversos , Compuestos Organofosforados/administración & dosificación , Compuestos Organofosforados/efectos adversos , Cuidados Paliativos/métodos , Radioterapia Adyuvante , Proteínas S100/análisis , Temozolomida , Vimentina/análisis , Ácido Zoledrónico
11.
Anticancer Res ; 32(4): 1485-7, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22493390

RESUMEN

UNLABELLED: Malignant pleural mesothelioma is a rare tumour. A three-modal strategy, comprising of surgery, radiotherapy and chemotherapy has been shown to be essential for appropriate management. Current literature evidences the importance of radiation therapy in the adjuvant setting for local control of the disease, as part of a multidisciplinary treatment, with increment of progression-free survival rate, but also of disease-free survival. CASE REPORT: At the beginning of 2007, a 26-year-old Peruvian woman was admitted to the hospital referring breathlessness and other non-specific symptoms such as fever and weight loss. After the diagnosis of pleural mesothelioma by thoracoscopic talc insufflation, combined with pleural biopsy, and total body computed tomographic scan, the patient underwent two cycles of neoadjuvant chemotherapy with pemetrexed (500 mg/m(2)) and cisplatin (75 mg/m(2)), followed by an extra-pleural pneumonectomy. After 6 months, the patient was treated with three-dimensional external beam radiation therapy to the left hemithorax. Computed tomographic scans, performed after the ending of the radiotherapy, integrated with positron-emission tomography, were all negative for neoplastic pathology. The patient remains in good health and free from recurrence at four years. CONCLUSION: This clinical case shows a disease-free survival interval of 4 years for malignant pleural mesothelioma. A good staging system and a combined treatment, involving surgery, neoadjuvant chemotherapy and adjuvant radiation therapy, represent a useful strategy not only to contain local disease progression, but even to increase disease-free survival in pleural mesothelioma.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Supervivencia sin Enfermedad , Mesotelioma/terapia , Neoplasias Pleurales/terapia , Adulto , Cisplatino/administración & dosificación , Terapia Combinada , Femenino , Glutamatos/administración & dosificación , Guanina/administración & dosificación , Guanina/análogos & derivados , Humanos , Mesotelioma/tratamiento farmacológico , Mesotelioma/cirugía , Pemetrexed , Neoplasias Pleurales/tratamiento farmacológico , Neoplasias Pleurales/cirugía , Tomografía de Emisión de Positrones , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda